ADAM12 ELISA 试剂盒
Our Local Distributor
北京 101111
Quick Overview for ADAM12 ELISA 试剂盒 (ABIN5068267)
抗原
See all ADAM12 ELISA试剂盒适用
检测方法
实验类型
应用范围
样品类型
-
-
Analytical Method
- Quantitative
-
灵敏度
- 0.030 ng/mL
-
产品特性
- ADAM12, ELISA Kit (Human)
-
组件
-
- ADAM12 Microplate 1x96 well polystyrene microplate (12 strips of 8 wells) coated with a mouse monoclonal antibody against human ADAM12.
- ADAM12 Conjugate 1x21ml of a monoclonal antibody against human ADAM12 conjugated to horseradish peroxidase with preservatives.
- ADAM12 Standard 3x(100 ng/vial) of recombinant human ADAM12 in a buffered protein solution with preservatives, lyophilized.
- Assay Diluent R 1x12ml of a buffered protein solution with preservatives. Calibrator Diluent R Concentrate 1x21ml of a buffered protein solution with preservatives.
- Wash Buffer Concentrate 1x21ml of a 25-fold concentrated solution of a buffered surfactant with preservatives.
- Color Reagent A 1x12.5ml of stabilized hydrogen peroxide.
- Color Reagent B 1x12.5ml of stabilized chromogen (tetramethylbenzidine).
- Stop Solution 1x6ml of a 2 N sulfuric acid.
-
-
-
-
板类型
- Pre-coated
-
实验流程
-
Principle:
- This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human ADAM12 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any ADAM12 present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked monoclonal antibody specific for human ADAM12 is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of ADAM12 bound in the initial step. The color development is stopped and the intensity of the color is measured.
-
实验精密度
-
Precision:
- Intra-assay:
- Mean (ng/ml): 1.39, 3.57, 6.84
- Standard Deviation: 0.057, 0.131, 0.235
- CV (%): 4.1, 3.7, 3.4
- Inter-assay:
- Mean (ng/ml): 1.43, 3.62, 6.74
- Standard Deviation: 0.079, 0.145, 0.299
- CV (%): 5.5, 4.0, 4.4
-
限制
- 仅限研究用
-
-
-
储存条件
- -20 °C
-
储存方法
- -20°C
-
-
- ADAM12 (ADAM Metallopeptidase Domain 12 (ADAM12))
-
别名
- ADAM12
-
背景
- Human ADAM12 (a disintegrin and metalloproteinase domain-containing protein 12) belongs to the ADAM metalloproteinase family. It is a single polypeptide chain composed of multiple domains, including the signal peptide, propeptide, metalloproteinase, disintegrin, cystein-rich, and EGF-like domains, as well as the transmembrane segment and cytoplasmic tail. Human ADAM12 has two alternatively transcribed forms: a membrane-anchored long form of 110kD and a 90kD shorter secreted form lacking the transmembrane domain and the cytoplasmic tail (1-3). ADAM12 is initially synthesized as an inactive enzyme. Its latency requires the coordination of a cysteine residue in the pro domain with the Zn2+ in the active site of the catalytic domain. It is then activated by a furin-like protease in the trans-Golgi apparatus through cleavage of the pro domain before it is transported to the cell surface and secreted as the active form (4, 5). Upon activation, the pro domain remains non-covalently attached to the mature enzyme (6). Endogenous inhibitors for ADAM12 include TIMP-3 and a2-macroglobulin (7). The soluble form of ADAM12 is detectable in various body fluids, such as serum and urine (8-10). Like other metalloproteinases, ADAM12 possesses gelatinase activity. It can cleave extracellular matrix proteins, such as gelatin, type IV collagen, and fibronectin (10). Thus, ADAM12 may play important roles in cell adhesion and extracellular matrix degradation. Over-expression of ADAM12 has been observed in various types of cancer. In mouse prostate cancer, ADAM12 is highly expressed in the carcinoma-associated stroma, and it is required for tumor progression (11). In a mouse breast cancer model, ADAM12 accelerates tumor progression through increasing the apoptotic sensitivity of normal stromal cells while rendering tumor cells more resistant to apoptosis (12, 13). Additionally, it has been reported that in breast cancer patients, ADAM12 has significantly increased amounts in the urine compared to healthy controls and higher levels of urinary ADAM12 seem to correlate with more aggressive phenotypes and more advanced stages (10).
-
途径
- EGFR Signaling Pathway
抗原 See all ADAM12 ELISA试剂盒
-